A Phase II Randomized Trial of Fish Oil in Patients With Acute Lung Injury (ALI)

Completed · Phase 2

Conditions studied: Respiratory Distress Syndrome, Adult, Acute Lung Injury, Acute Respiratory Distress Syndrome

In brief

The purpose of this study is to determine whether fish oil (containing omega-3 fatty acids) given enterally is safe and effective in reducing lung and systemic inflammation seen in acute lung injury.

Key facts

Study ID: NCT00351533
Run by: University of Washington
People needed: 90
Starts: 2006-07-01
Expected to finish: 2009-08-01
Last updated by the study team: 2011-10-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Requiring positive-pressure mechanical ventilation
ALI criteria: PaO2/FiO2 <300, bilateral infiltrates on chest radiograph, no left atrial hypertension
Age > 17 years

You may not qualify if…

Expected ICU length of stay <48 hours
Unable to undergo bronchoalveolar lavage at enrollment
Unable to obtain enteral access
Post-cardiac arrest with suspected significant anoxic brain injury
Expected survival < 28 days
Pregnant
Platelet count < 30,000, active bleeding, or international normalized ratio (INR)>3.0
History of ventricular tachycardia or fibrillation
Receiving recombinant human activated protein C (rh-APC) for sepsis
Acquired immune deficiency syndrome (AIDS) with CD4 count < 200
Metastatic cancer
History of bone marrow, lung, liver, cardiac, kidney, or pancreas transplant

Where it is running

St. Alphonsus Medical Center — Boise, Idaho, United States
Oregon Health Sciences University — Portland, Oregon, United States
University of Vermont/Fletcher Allen Health Care — Burlington, Vermont, United States
Harborview Medical Center — Seattle, Washington, United States
St. Michael's Hospital — Toronto, Ontario, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.